Drospirenone: a Latin American perspective for oestrogen-free oral contraception

References

• Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf. 2014;5(5):201–213.
   PubMedGoogle Scholar
• United Nations, Department of Economic and Social Affairs, Population Division. 2018. World Contraceptive Use 2018 (POP/DB/CP/Rev2018).
   Google Scholar
• Ponce de León RG, Ewerling F, Serruya SJ, et al. Contraceptive use in Latin America and the Caribbean with a focus on long-acting reversible contraceptives: prevalence and inequalities in 23 countries. Lancet Glob Health. 2019;7(2):e227–e235.
   PubMed Web of Science ®Google Scholar
• Beller JP, McCartney CR. Cardiovascular risk and combined oral contraceptives: clinical decisions in settings of uncertainty. Am J Obstet Gynecol. 2013;208(1):39–41.
   PubMed Web of Science ®Google Scholar
• Kaminski P, Szpotanska-Sikorska M, Wielgos M. Cardiovascular risk and the use of oral contraceptives. Neuro Endocrinol Lett. 2013;34(7):587–589.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. Fifth Edition, 2015. Disponible en; [cited 2020 Jul]. Available from: https://bit.ly/2SNhZJg
   Google Scholar
• ACOG. ACOG Practice Bulletin No. 206: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133(2):e128–e150.
   PubMed Web of Science ®Google Scholar
• Quesada-Moreno M. Sociedad Española de Ginecología y Obstetricia. Protocolos SEGO/SEC: Anticoncepción con Sólo Gestágenos. Disponible en; [cited 2020 Jul]. Available from: https://bit.ly/2CbadUd.
   Google Scholar
• Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92(5):439–444.
   PubMed Web of Science ®Google Scholar
• Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94(6):678–700.
   PubMed Web of Science ®Google Scholar
• Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(10):1042–1052.
   PubMed Web of Science ®Google Scholar
• Raymond EG. Progestin-only pills. In: Hatcher RA, Trussell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, editor. Contraceptive technology, 19th ed. New York: Ardent Media, Inc.; 2007. p. 181–191.
   Google Scholar
• Shulman LP. A review of drospirenone for safety and tolerability and effects on endometrial safety and lipid parameters contrasted with medroxyprogesterone acetate, levonorgestrel, and micronized progesterone. J Womens Health. 2006;15(5):584–590.
   Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005;8(Suppl 3):4–12.
   PubMedGoogle Scholar
• Duijkers IJ, Heger-Mahn D, Drouin D, et al. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015;20(6):419–427.
   PubMed Web of Science ®Google Scholar
• Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98(12):1549–1557.
   PubMed Web of Science ®Google Scholar
• Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016;93(4):303–309.
   PubMed Web of Science ®Google Scholar
• Aubeny E, Buhler M, Colau JC, et al. Oral contraception: patterns of non-compliance. The Coraliance study. Eur J Contracept Reprod Health Care. 2002;7(3):155–161.
   PubMed Web of Science ®Google Scholar
• Słopień R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Prz Menopauzalny. 2018;17(1):1–4.
   PubMedGoogle Scholar
• Lortscher D, Admani S, Satur N, et al. Hormonal contraceptives and acne: a retrospective analysis of 2147 patients. J Drugs Dermatol. 2016;15(6):670–674.
   PubMed Web of Science ®Google Scholar
• De Leo V, Morgante G, Piomboni P, et al. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007;88(1):113–117.
   PubMed Web of Science ®Google Scholar
• González-Hernando C, Souza de Almeida M, Martín-Villamor P, et al. La píldora anticonceptiva a debate. Enfermería Universitaria. 2013;10(3):98–104.
   Google Scholar
• Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287–294.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32(9):749–751.
   PubMed Web of Science ®Google Scholar
• Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33(7):673–689.
   PubMed Web of Science ®Google Scholar
• Cominato L, Di Biagio GF, Lellis D, et al. Obesity prevention: strategies and challenges in Latin America. Curr Obes Rep. 2018;7(2):97–104.
   PubMed Web of Science ®Google Scholar
• Spinedi E, Cardinali DP. The polycystic ovary syndrome and the metabolic syndrome: a possible chronobiotic-cytoprotective adjuvant therapy. Int J Endocrinol. 2018;2018:1349868.
   PubMed Web of Science ®Google Scholar
• Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: a systematic review. Contraception. 2016;94(6):590–604.
   PubMed Web of Science ®Google Scholar
• Merki-Feld GS, Skouby S, Serfaty D, et al. European society of contraception statement on contraception in obese women. Eur J Contracept Reprod Health Care. 2015;20(1):19–28.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Ramesh S, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016;(8):CD008815.
   Google Scholar
• Lanas F, Bazzano L, Rubinstein A, et al. Prevalence, distributions and determinants of obesity and central obesity in the Southern Cone of America. PLoS One. 2016;11(10):e0163727.
   PubMed Web of Science ®Google Scholar
• West R. Tobacco smoking: health impact, prevalence, correlates and interventions. Psychol Health. 2017;32(8):1018–1036.
   PubMed Web of Science ®Google Scholar
• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–2260.
   PubMed Web of Science ®Google Scholar
• Bardach A, Perdomo HA, Gándara RA, et al. Income and smoking prevalence in Latin America: a systematic review and meta-analysis. Rev Panam Salud Publica. 2016;40(4):263–271.
   PubMed Web of Science ®Google Scholar
• Organización Panamericana de la Salud. Informe sobre Control del Tabaco para la Región de las Américas, 2011. Disponible en; [cited 2020 Jul]. Available from: https://bit.ly/2Hd4MIH.
   Google Scholar
• Valdés-Salgado R, Hernández-Avila M, Sepúlveda-Amor J. El consumo de tabaco en la Región Americana: elementos para un programa de acción. Salud Pública Méx. 2002;44 (Supl 1):S125–S135.
   PubMedGoogle Scholar
• Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001;345(25):1787–1793.
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Palmer JR, Rao RS, et al. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med. 2001;161(8):1065–1070.
   PubMedGoogle Scholar
• Khader YS, Rice J, John L, et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception. 2003;68(1):11–17.
   PubMed Web of Science ®Google Scholar
• Wang Q, Würtz P, Auro K, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45(5):1445–1457.
   PubMed Web of Science ®Google Scholar
• Ponte-Negretti CI, Isea-Perez JE, Lorenzatti AJ, et al. Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment: expert’s position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS). Int J Cardiol. 2017;243:516–522.
   PubMed Web of Science ®Google Scholar
• Preston RA, White WB, Pitt B, et al. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18(6):797–804.
   PubMed Web of Science ®Google Scholar
• Rubinstein AL, Irazola VE, Calandrelli M, et al. Prevalence, awareness, treatment, and control of hypertension in the southern cone of Latin America. Am J Hypertens. 2016;29(12):1343–1352.
   PubMed Web of Science ®Google Scholar
• Neal S, Harvey C, Chandra-Mouli V, et al. Trends in adolescent first births in five countries in Latin America and the Caribbean: disaggregated data from demographic and health surveys. Reprod Health. 2018;15(1):146.
   PubMedGoogle Scholar
• Cibula D, Skrenkova J, Hill M, et al. Lowdose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. Eur J Endocrinol. 2012;166(6):1003–1011.
   PubMed Web of Science ®Google Scholar
• Pikkarainen E, Lehtonen-Veromaa M, Mottonen T, et al. Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception. 2008;78(3):226–231.
   PubMed Web of Science ®Google Scholar
• Ott MA, Sucato GS, Committee on Adolescence. Contraception for adolescents. Pediatrics. 2014;134(4):e1257–e1281.
   PubMed Web of Science ®Google Scholar
• Hadji P, Colli E, Regidor PA. Bone health in estrogen-free contraception. Osteoporos Int. 2019;30(12):2391–2400.
   PubMed Web of Science ®Google Scholar
• Palacios S, López J, Celis C, et al. Multicentre, open-label trial to assess the safety and tolerability of LF111 (Drospirenone 4.0 mg) over 6 cycles in female adolescents, with a 7-cycle extension phase. Clinical Trial Report CF111/304 In press.
   Google Scholar
• Monterrosa A. Anticonceptivos orales de solo progestina. Rev Colomb Obstet Ginecol. 2006;57(1):45–53.
   Google Scholar
• Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Drospirenone [updated 2020 Feb 17]. Disponible en; [cited 2020 Jul]. Available from: https://bit.ly/2z9nfmW.
   Google Scholar
• Del Savio MC, De Fata R, Facchinetti F, et al. Drospirenone 4 mg-only pill (DOP) in 24 + 4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–694.
   PubMed Web of Science ®Google Scholar